Chronic lymphocytic leukemia in 2007: Prognostic factors and therapeutic approaches

Ayalew Tefferi, Susan O'Brien

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Major prognostic factors in chronic lymphocytic leukemia (CLL) include chromosomal abnormalities that can be identified by conventional cytogenetic analysis or fluorescence in situ hybridization; 17p- and 11q- are associated with a poor prognosis; 6q- and 12q trisomy are associated with an intermediate prognosis; and 13q- (the most frequent cytogenetic abnormality in CLL) is a favorable marker. Other prognostic markers include presence (favorable) or absence of IgVH somatic mutations, detected by polymerase chain reaction, and high levels of expression of CD38 and ZAP70 (both unfavorable) measured by flow cytometry. A recent study showed that median treatment-free survival was not reached in ZAP70-negative/CD38-negative patients (51% of study population), compared with 12 months in patients positive for both (17%) and 42 months in those positive for one (31%). However, the therapeutic utilization of these prognostic factors, over and above that dictated by clinical staging systems, remains to be determined. Regardless, it is currently reasonable to use cytogenetic information as well as ZAP70 and CD38 expression status to complement prognostication by clinical staging and to determine frequency of monitoring. When treatment is required, first-line treatment presently consists of FCR (fludarabine, cyclophosphamide, rituximab), which is associated with a 95% overall response rate and an unprecedented 70% complete remission rate. However, such therapy has not been shown to improve overall survival, and it is reasonable to continue considering first-line treatment with chlorambucil/prednisone instead for older patients. In general, patients with poor prognostic factors experience shorter progression-free survival after treatment, which is particularly true for patients with 17p-, who also respond poorly to standard therapy. A number of novel agents are in development for treatment of relapse. Allogeneic transplantation should not be omitted from consideration in relapse, because it offers a chance for cure.

Original languageEnglish (US)
Pages (from-to)11-16
Number of pages6
JournalCommunity Oncology
Volume4
Issue number12 SUPPL. 5
StatePublished - Dec 2007

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Chromosome Aberrations
Chlorambucil
Recurrence
Survival
Cytogenetic Analysis
Homologous Transplantation
Prednisone
Fluorescence In Situ Hybridization
Cytogenetics
Cyclophosphamide
Disease-Free Survival
Flow Cytometry
Polymerase Chain Reaction
Mutation

ASJC Scopus subject areas

  • Oncology

Cite this

Chronic lymphocytic leukemia in 2007 : Prognostic factors and therapeutic approaches. / Tefferi, Ayalew; O'Brien, Susan.

In: Community Oncology, Vol. 4, No. 12 SUPPL. 5, 12.2007, p. 11-16.

Research output: Contribution to journalArticle

@article{bb7f2a1cdb9f404fae4faa2aff24955c,
title = "Chronic lymphocytic leukemia in 2007: Prognostic factors and therapeutic approaches",
abstract = "Major prognostic factors in chronic lymphocytic leukemia (CLL) include chromosomal abnormalities that can be identified by conventional cytogenetic analysis or fluorescence in situ hybridization; 17p- and 11q- are associated with a poor prognosis; 6q- and 12q trisomy are associated with an intermediate prognosis; and 13q- (the most frequent cytogenetic abnormality in CLL) is a favorable marker. Other prognostic markers include presence (favorable) or absence of IgVH somatic mutations, detected by polymerase chain reaction, and high levels of expression of CD38 and ZAP70 (both unfavorable) measured by flow cytometry. A recent study showed that median treatment-free survival was not reached in ZAP70-negative/CD38-negative patients (51{\%} of study population), compared with 12 months in patients positive for both (17{\%}) and 42 months in those positive for one (31{\%}). However, the therapeutic utilization of these prognostic factors, over and above that dictated by clinical staging systems, remains to be determined. Regardless, it is currently reasonable to use cytogenetic information as well as ZAP70 and CD38 expression status to complement prognostication by clinical staging and to determine frequency of monitoring. When treatment is required, first-line treatment presently consists of FCR (fludarabine, cyclophosphamide, rituximab), which is associated with a 95{\%} overall response rate and an unprecedented 70{\%} complete remission rate. However, such therapy has not been shown to improve overall survival, and it is reasonable to continue considering first-line treatment with chlorambucil/prednisone instead for older patients. In general, patients with poor prognostic factors experience shorter progression-free survival after treatment, which is particularly true for patients with 17p-, who also respond poorly to standard therapy. A number of novel agents are in development for treatment of relapse. Allogeneic transplantation should not be omitted from consideration in relapse, because it offers a chance for cure.",
author = "Ayalew Tefferi and Susan O'Brien",
year = "2007",
month = "12",
language = "English (US)",
volume = "4",
pages = "11--16",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "12 SUPPL. 5",

}

TY - JOUR

T1 - Chronic lymphocytic leukemia in 2007

T2 - Prognostic factors and therapeutic approaches

AU - Tefferi, Ayalew

AU - O'Brien, Susan

PY - 2007/12

Y1 - 2007/12

N2 - Major prognostic factors in chronic lymphocytic leukemia (CLL) include chromosomal abnormalities that can be identified by conventional cytogenetic analysis or fluorescence in situ hybridization; 17p- and 11q- are associated with a poor prognosis; 6q- and 12q trisomy are associated with an intermediate prognosis; and 13q- (the most frequent cytogenetic abnormality in CLL) is a favorable marker. Other prognostic markers include presence (favorable) or absence of IgVH somatic mutations, detected by polymerase chain reaction, and high levels of expression of CD38 and ZAP70 (both unfavorable) measured by flow cytometry. A recent study showed that median treatment-free survival was not reached in ZAP70-negative/CD38-negative patients (51% of study population), compared with 12 months in patients positive for both (17%) and 42 months in those positive for one (31%). However, the therapeutic utilization of these prognostic factors, over and above that dictated by clinical staging systems, remains to be determined. Regardless, it is currently reasonable to use cytogenetic information as well as ZAP70 and CD38 expression status to complement prognostication by clinical staging and to determine frequency of monitoring. When treatment is required, first-line treatment presently consists of FCR (fludarabine, cyclophosphamide, rituximab), which is associated with a 95% overall response rate and an unprecedented 70% complete remission rate. However, such therapy has not been shown to improve overall survival, and it is reasonable to continue considering first-line treatment with chlorambucil/prednisone instead for older patients. In general, patients with poor prognostic factors experience shorter progression-free survival after treatment, which is particularly true for patients with 17p-, who also respond poorly to standard therapy. A number of novel agents are in development for treatment of relapse. Allogeneic transplantation should not be omitted from consideration in relapse, because it offers a chance for cure.

AB - Major prognostic factors in chronic lymphocytic leukemia (CLL) include chromosomal abnormalities that can be identified by conventional cytogenetic analysis or fluorescence in situ hybridization; 17p- and 11q- are associated with a poor prognosis; 6q- and 12q trisomy are associated with an intermediate prognosis; and 13q- (the most frequent cytogenetic abnormality in CLL) is a favorable marker. Other prognostic markers include presence (favorable) or absence of IgVH somatic mutations, detected by polymerase chain reaction, and high levels of expression of CD38 and ZAP70 (both unfavorable) measured by flow cytometry. A recent study showed that median treatment-free survival was not reached in ZAP70-negative/CD38-negative patients (51% of study population), compared with 12 months in patients positive for both (17%) and 42 months in those positive for one (31%). However, the therapeutic utilization of these prognostic factors, over and above that dictated by clinical staging systems, remains to be determined. Regardless, it is currently reasonable to use cytogenetic information as well as ZAP70 and CD38 expression status to complement prognostication by clinical staging and to determine frequency of monitoring. When treatment is required, first-line treatment presently consists of FCR (fludarabine, cyclophosphamide, rituximab), which is associated with a 95% overall response rate and an unprecedented 70% complete remission rate. However, such therapy has not been shown to improve overall survival, and it is reasonable to continue considering first-line treatment with chlorambucil/prednisone instead for older patients. In general, patients with poor prognostic factors experience shorter progression-free survival after treatment, which is particularly true for patients with 17p-, who also respond poorly to standard therapy. A number of novel agents are in development for treatment of relapse. Allogeneic transplantation should not be omitted from consideration in relapse, because it offers a chance for cure.

UR - http://www.scopus.com/inward/record.url?scp=37549007103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549007103&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:37549007103

VL - 4

SP - 11

EP - 16

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 12 SUPPL. 5

ER -